NCT07309497
- Conditions
- Bispecific Antibody, Blood Protein Disorders, CART Therapy, +18 more
- Locations
-
- Inselspital Bern Bern, Switzerland
- Universitätsspital Zürich Zurich, Switzerland
Clinical trial condition
Bispecific Antibody
Explore clinical trials studying Bispecific Antibody. Study availability and eligibility vary by location and protocol.
5 public trials
1 recruiting study
Bispecific Antibody trial results
Not Yet Recruiting
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
NCT07231250
- Conditions
- Bispecific Antibody, Chemo-free Therapy, DLBCL - Diffuse Large B Cell Lymphoma, +7 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China
Not Yet Recruiting
A Phase II Randomized Trial of Neoadjuvant Ivonescimab or Penpulimab Plus Chemotherapy in Resectable NSCLC
NCT07086326
- Conditions
- AK112, Bispecific Antibody, Immunotherapy, +2 more
- Locations
-
- Peking University People's Hospital Beijing, Beijing Municipality, China
- Hunan Cancer Hospital Changsha, Hunan, China
- Shanghai Chest Hospital Shanghai, Shanghai Municipality, China
- The First Affiliated Hospital of Xi'an Jiaotong University Xi’an, Shanxi, China
NCT06946836
- Conditions
- Bispecific Antibody, Neoadjuvant Therapy, Resectable Non-small Cell Lung Cancer
- Locations
-
Not specified
Completed
A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.
NCT05228470
- Conditions
- BCMA, BCMA-CD3 Bispecific, Bispecific, +23 more
- Locations
-
- Fujian Medical University Union Hospital Fuzhou, Fujian, China
- Guangdong Provincial People's Hospital Guangzhou, Guangdong, China
- Nanfang Hospital of Southern Medical University Guangzhou, Guangdong, China
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China